PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Tikcro Technologies To Present Unique Properties of a Novel CTLA-4 Antibody at the AACR Annual Meeting 2019 in the U.S.

Tikcro Technologies To Present Unique Properties of a Novel CTLA-4 Antibody at the AACR Annual Meeting 2019 in the U.S.

by Tony Allen
April 26, 2019
in Medical
Reading Time: 2 mins read
0

REHOVOT, Israel, March 14, 2019 /PRNewswire/ — Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage antibody immunotherapy company leveraging a novel mimitope approach for antibody generation, today announced that it will present a scientific poster featuring the unique properties of a novel CTLA-4 antibody at the American Association for Cancer Research (AACR) Annual Meeting 2019 to be held at the Georgia World Congress Center in Atlanta, GA on Friday, March 29, 2019 – Wednesday, April 3, 2019.

The poster titled “A CTLA4 antibody with enhanced properties” will feature TikAb, a full human CTLA-4 antibody, and in-vitro and in-vivo assay results with comparative data to the existing treatment will be presented.

Title: A CTLA-4 antibody with enhanced properties

Date: Tuesday, April 2, 2019

Time: 8:00am – 12:00pm ET

Session: Immune Checkpoints 1

Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 24

Additional abstract information is available here: https://www.abstractsonline.com/pp8/#!/6812/presentation/2667

About Tikcro Technologies


Tikcro Technologies Ltd. (OTCQB: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro’s website at www.tikcro.com.

SOURCE Tikcro Technologies Ltd.

Related Links

https://www.tikcro.com

Read More

Previous Post

Wicheeda Deposit 30 Tonne Bulk Sample Returns 4.81% Light Rare Earth Oxide Head Grade

Next Post

4 cryptocurrency Twitter takes you really need to read

Tony Allen

Tony Allen received a bachelor’s degree in journalism from the University of South Florida in 2011, specializing in feature writing and reporting on sports and events.

Related Posts

Medical

FDA advisory panel recommends Moderna, Johnson & Johnson vaccine booster shots

October 18, 2021
0
Medical

Walgreens invests $5.5B to accelerate new healthcare business segment

October 18, 2021
0
Medical

Mayo Clinic to study respiratory muscle training as long COVID treatment

October 18, 2021
0
Medical

Anthem, Providence tap Vim for value-based care platform deployment

October 25, 2021
0
Medical

Healthcare lost 17,500 jobs in September amid ongoing labor shortage

October 25, 2021
0
Medical

Cigna divests life, accident and supplemental benefits businesses for $5.75B

October 25, 2021
0
Next Post
4 cryptocurrency Twitter takes you really need to read

4 cryptocurrency Twitter takes you really need to read

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.